Cargando…

Health care delivery system contributions to management of newly diagnosed prostate cancer

BACKGROUND: Despite clinical guidelines advocating for use of conservative management in specific clinical scenarios for men with prostate cancer, there continues to be tremendous variation in its uptake. This variation may be amplified among men with competing health risks, for whom treatment decis...

Descripción completa

Detalles Bibliográficos
Autores principales: Krampe, Noah, Kaufman, Samuel R., Oerline, Mary K., Hill, Dawson, Caram, Megan E. V., Shahinian, Vahakn B., Hollenbeck, Brent K., Maganty, Avinash
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10501260/
https://www.ncbi.nlm.nih.gov/pubmed/37475511
http://dx.doi.org/10.1002/cam4.6349
_version_ 1785106082814754816
author Krampe, Noah
Kaufman, Samuel R.
Oerline, Mary K.
Hill, Dawson
Caram, Megan E. V.
Shahinian, Vahakn B.
Hollenbeck, Brent K.
Maganty, Avinash
author_facet Krampe, Noah
Kaufman, Samuel R.
Oerline, Mary K.
Hill, Dawson
Caram, Megan E. V.
Shahinian, Vahakn B.
Hollenbeck, Brent K.
Maganty, Avinash
author_sort Krampe, Noah
collection PubMed
description BACKGROUND: Despite clinical guidelines advocating for use of conservative management in specific clinical scenarios for men with prostate cancer, there continues to be tremendous variation in its uptake. This variation may be amplified among men with competing health risks, for whom treatment decisions are not straightforward. The degree to which characteristics of the health care delivery system explain this variation remains unclear. METHODS: Using national Medicare data, men with newly diagnosed prostate cancer between 2014 and 2019 were identified. Hierarchical logistic regression models were used to assess the association between use of treatment and health care delivery system determinants operating at the practice level, which included measures of financial incentives (i.e., radiation vault ownership), practice organization (i.e., single specialty vs. multispecialty groups), and the health care market (i.e., competition). Variance was partitioned to estimate the relative influence of patient and practice characteristics on the variation in use of treatment within strata of noncancer mortality risk groups. RESULTS: Among 62,507 men with newly diagnosed prostate cancer, the largest variation in the use of treatment between practices was observed for men with high and very high‐risk of noncancer mortality (range of practice‐level rates of treatment for high: 57%–71% and very high: 41%–61%). Addition of health care delivery system determinants measured at the practice level explained 13% and 15% of the variation in use of treatment among men with low and intermediate risk of noncancer mortality in 10 years, respectively. Conversely, these characteristics explained a larger share of the variation in use of treatment among men with high and very high‐risk of noncancer mortality (26% and 40%, respectively). CONCLUSIONS: Variation among urology practices in use of treatment was highest for men with high and very high‐risk noncancer mortality. Practice characteristics explained a large share of this variation.
format Online
Article
Text
id pubmed-10501260
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-105012602023-09-15 Health care delivery system contributions to management of newly diagnosed prostate cancer Krampe, Noah Kaufman, Samuel R. Oerline, Mary K. Hill, Dawson Caram, Megan E. V. Shahinian, Vahakn B. Hollenbeck, Brent K. Maganty, Avinash Cancer Med RESEARCH ARTICLES BACKGROUND: Despite clinical guidelines advocating for use of conservative management in specific clinical scenarios for men with prostate cancer, there continues to be tremendous variation in its uptake. This variation may be amplified among men with competing health risks, for whom treatment decisions are not straightforward. The degree to which characteristics of the health care delivery system explain this variation remains unclear. METHODS: Using national Medicare data, men with newly diagnosed prostate cancer between 2014 and 2019 were identified. Hierarchical logistic regression models were used to assess the association between use of treatment and health care delivery system determinants operating at the practice level, which included measures of financial incentives (i.e., radiation vault ownership), practice organization (i.e., single specialty vs. multispecialty groups), and the health care market (i.e., competition). Variance was partitioned to estimate the relative influence of patient and practice characteristics on the variation in use of treatment within strata of noncancer mortality risk groups. RESULTS: Among 62,507 men with newly diagnosed prostate cancer, the largest variation in the use of treatment between practices was observed for men with high and very high‐risk of noncancer mortality (range of practice‐level rates of treatment for high: 57%–71% and very high: 41%–61%). Addition of health care delivery system determinants measured at the practice level explained 13% and 15% of the variation in use of treatment among men with low and intermediate risk of noncancer mortality in 10 years, respectively. Conversely, these characteristics explained a larger share of the variation in use of treatment among men with high and very high‐risk of noncancer mortality (26% and 40%, respectively). CONCLUSIONS: Variation among urology practices in use of treatment was highest for men with high and very high‐risk noncancer mortality. Practice characteristics explained a large share of this variation. John Wiley and Sons Inc. 2023-07-20 /pmc/articles/PMC10501260/ /pubmed/37475511 http://dx.doi.org/10.1002/cam4.6349 Text en © 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle RESEARCH ARTICLES
Krampe, Noah
Kaufman, Samuel R.
Oerline, Mary K.
Hill, Dawson
Caram, Megan E. V.
Shahinian, Vahakn B.
Hollenbeck, Brent K.
Maganty, Avinash
Health care delivery system contributions to management of newly diagnosed prostate cancer
title Health care delivery system contributions to management of newly diagnosed prostate cancer
title_full Health care delivery system contributions to management of newly diagnosed prostate cancer
title_fullStr Health care delivery system contributions to management of newly diagnosed prostate cancer
title_full_unstemmed Health care delivery system contributions to management of newly diagnosed prostate cancer
title_short Health care delivery system contributions to management of newly diagnosed prostate cancer
title_sort health care delivery system contributions to management of newly diagnosed prostate cancer
topic RESEARCH ARTICLES
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10501260/
https://www.ncbi.nlm.nih.gov/pubmed/37475511
http://dx.doi.org/10.1002/cam4.6349
work_keys_str_mv AT krampenoah healthcaredeliverysystemcontributionstomanagementofnewlydiagnosedprostatecancer
AT kaufmansamuelr healthcaredeliverysystemcontributionstomanagementofnewlydiagnosedprostatecancer
AT oerlinemaryk healthcaredeliverysystemcontributionstomanagementofnewlydiagnosedprostatecancer
AT hilldawson healthcaredeliverysystemcontributionstomanagementofnewlydiagnosedprostatecancer
AT carammeganev healthcaredeliverysystemcontributionstomanagementofnewlydiagnosedprostatecancer
AT shahinianvahaknb healthcaredeliverysystemcontributionstomanagementofnewlydiagnosedprostatecancer
AT hollenbeckbrentk healthcaredeliverysystemcontributionstomanagementofnewlydiagnosedprostatecancer
AT magantyavinash healthcaredeliverysystemcontributionstomanagementofnewlydiagnosedprostatecancer